Corebridge Financial Inc. Has $3.61 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Corebridge Financial Inc. decreased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 24.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 86,706 shares of the company's stock after selling 28,775 shares during the quarter. Corebridge Financial Inc.'s holdings in Moderna were worth $3,605,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP raised its position in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares during the period. Howard Capital Management Inc. boosted its position in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Moderna by 0.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after buying an additional 345 shares during the period. Larson Financial Group LLC increased its position in shares of Moderna by 39.1% in the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after buying an additional 356 shares in the last quarter. Finally, New Insight Wealth Advisors raised its stake in Moderna by 4.4% during the 4th quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after buying an additional 358 shares during the period. Institutional investors own 75.33% of the company's stock.

Remove Ads

Moderna Price Performance

NASDAQ MRNA traded up $0.56 on Wednesday, hitting $27.72. 11,786,637 shares of the stock were exchanged, compared to its average volume of 6,926,124. The company has a market capitalization of $10.72 billion, a PE ratio of -2.99 and a beta of 1.86. The business's fifty day moving average is $34.43 and its 200 day moving average is $43.55. Moderna, Inc. has a 52 week low of $26.32 and a 52 week high of $170.47.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Berenberg Bank boosted their price objective on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. UBS Group dropped their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.